Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Leopold

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of Global Oncology|December 21, 2019
Expanding Coverage of Oncology Drugs in an Aging, Upper-Middle-Income Country: Analyses of Public and Private Expenditures in ChileVeronica Vargas, Christine Leopold, Marianela Castillo-Riquelme, et al.
Journal of the National Cancer Institute|May 23, 2018
Defining Value of Cancer Therapeutics-A Health System PerspectiveChristine Leopold, Jeffrey M Peppercorn, S Yousuf Zafar, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 6, 2020
The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from MassachusettsChristine Leopold, Rebecca L Haffajee, Christine Y Lu, et al.
Clinical Pharmacology and Therapeutics|June 24, 2026
Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused RegistriesManon C Wilpshaar, Doranne Hilarius, Luisa Prada, et al.
Health Affairs Scholar|March 19, 2026
A multi-stakeholder survey on communicating cost-effectiveness uncertainties to stakeholders: a case study of ICERJan-Willem Versteeg, Wim G Goettsch, Aukje K Mantel-Teeuwisse, et al.
Health Policy (Amsterdam, Netherlands)|July 26, 2018
An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countriesSteven G Morgan, Chester B Good, Christine Leopold, et al.
International Journal of Technology Assessment in Health Care|November 17, 2025
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the NetherlandsJan-Willem Versteeg, Noraly Stam, Aukje K Mantel-Teeuwisse, et al.
British Journal of Clinical Pharmacology|May 14, 2026
Decoding RNA regulation: Challenges and opportunities for RNA-based therapies in EuropeOlivia C Lewis, Christine Leopold, Joyce M Hoek, et al.
Pharmacoeconomics|October 5, 2024
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their SuitabilityMarcelien H E Callenbach, Rick A Vreman, Christine Leopold, et al.
Health Policy (Amsterdam, Netherlands)|October 22, 2011
Differences in external price referencing in Europe: a descriptive overviewChristine Leopold, Sabine Vogler, A K Mantel-Teeuwisse, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Global Oncology|December 21, 2019
Expanding Coverage of Oncology Drugs in an Aging, Upper-Middle-Income Country: Analyses of Public and Private Expenditures in ChileVeronica Vargas, Christine Leopold, Marianela Castillo-Riquelme, et al.
Journal of the National Cancer Institute|May 23, 2018
Defining Value of Cancer Therapeutics-A Health System PerspectiveChristine Leopold, Jeffrey M Peppercorn, S Yousuf Zafar, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 6, 2020
The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from MassachusettsChristine Leopold, Rebecca L Haffajee, Christine Y Lu, et al.
Clinical Pharmacology and Therapeutics|June 24, 2026
Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused RegistriesManon C Wilpshaar, Doranne Hilarius, Luisa Prada, et al.
Health Affairs Scholar|March 19, 2026
A multi-stakeholder survey on communicating cost-effectiveness uncertainties to stakeholders: a case study of ICERJan-Willem Versteeg, Wim G Goettsch, Aukje K Mantel-Teeuwisse, et al.
Health Policy (Amsterdam, Netherlands)|July 26, 2018
An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countriesSteven G Morgan, Chester B Good, Christine Leopold, et al.
International Journal of Technology Assessment in Health Care|November 17, 2025
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the NetherlandsJan-Willem Versteeg, Noraly Stam, Aukje K Mantel-Teeuwisse, et al.
British Journal of Clinical Pharmacology|May 14, 2026
Decoding RNA regulation: Challenges and opportunities for RNA-based therapies in EuropeOlivia C Lewis, Christine Leopold, Joyce M Hoek, et al.
Pharmacoeconomics|October 5, 2024
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their SuitabilityMarcelien H E Callenbach, Rick A Vreman, Christine Leopold, et al.
Health Policy (Amsterdam, Netherlands)|October 22, 2011
Differences in external price referencing in Europe: a descriptive overviewChristine Leopold, Sabine Vogler, A K Mantel-Teeuwisse, et al.
Pageof 4